Cresco Labs (CRLBF) Income from Discontinued Operations (2022 - 2024)
Cresco Labs (CRLBF) posted Income from Discontinued Operations of 19016000.0 for Q3 2024, down 85.74% on a QoQ basis from 10238000.0 in Q2 2024, and down 430.94% year-over-year from 5746000.0 in Q4 2023.
Cresco Labs (CRLBF) Income from Discontinued Operations (2022 - 2024) Analysis & Trends
Cresco Labs' Income from Discontinued Operations history runs 3 years deep, the most recent figure standing at 19016000.0 for Q3 2024.
- Quarterly Income from Discontinued Operations fell 430.94% year-over-year to 19016000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 31458000.0 (changed N/A YoY) and the FY2023 annual result came in at 32950000.0, up 62.95% from the prior year.
- Income from Discontinued Operations was 19016000.0 for Q3 2024 at Cresco Labs, down from 10238000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 5746000.0 in Q3 2023 and bottomed at 23761000.0 in Q4 2022.
- A 3-year average of 11043800.0 and a median of 10238000.0 in 2024 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2023 — Income from Discontinued Operations jumped 66.54% — and 2024, when it slumped 430.94%.
- Cresco Labs' Income from Discontinued Operations stood at 23761000.0 in 2022, then soared by 66.54% to 7950000.0 in 2023, then slumped by 139.19% to 19016000.0 in 2024.
- Business Quant data shows CRLBF's Income from Discontinued Operations at 19016000.0 in Q3 2024, 10238000.0 in Q2 2024, and 7950000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Cresco Labs | 245.85 Mn | 182.28 Mn | 75.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -19.02 Mn |
| Jun 30, 2024 | -10.24 Mn |
| Dec 31, 2023 | -7.95 Mn |
| Sep 30, 2023 | 5.75 Mn |
| Dec 31, 2022 | -23.76 Mn |